TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) just unveiled an announcement.
Lepu Biopharma Co., Ltd. announced a significant licensing transaction with Excalipoint, granting them exclusive rights to develop and commercialize two pre-clinical assets worldwide. This strategic move is part of Lepu Biopharma’s long-term strategy to globalize its pipeline and technologies, allowing the company to focus on advancing its research priorities and accelerating the commercialization of late-stage products. The deal includes an upfront payment of $10 million, potential milestone payments up to $847.5 million, and sales royalties. Additionally, Excalipoint will conduct a series A financing round, raising $41 million, which complements the licensing transaction and supports the company’s growth strategy.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. operates in the biopharmaceutical industry, focusing on the development of innovative therapies. The company is known for its proprietary T cell engager-TOPAbody platform and is actively involved in the research and development of next-generation ADC drugs and IO bi/tri specific antibodies.
Average Trading Volume: 29,032,471
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.42B
For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.